Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)

BACKGROUND: The phase 3 MPACT trial in patients with metastatic pancreatic cancer demonstrated superior efficacy of nab-paclitaxel (nab-P) + gemcitabine (Gem) vs Gem monotherapy for all endpoints examined including overall survival, the primary endpoint. In the MPACT trial, patients were treated unt...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogel, Arndt, Römmler-Zehrer, Josefine, Li, Jack Shiansong, McGovern, Desmond, Romano, Alfredo, Stahl, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073820/
https://www.ncbi.nlm.nih.gov/pubmed/27769210
http://dx.doi.org/10.1186/s12885-016-2798-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5073820/
https://www.ncbi.nlm.nih.gov/pubmed/27769210
http://dx.doi.org/10.1186/s12885-016-2798-8

Ejemplares similares